At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 251 enrolled
Drug / intervention
Levetiracetamdrug
Likely dose
Levetiracetam 500 mg oral tabletsAI-extracted
Key inclusion· 3
- ✓Diagnosis of epilepsy with partial seizures, with or without secondary generalization
- ✓3-42 partial seizures in the 3 months before baseline visit
- ✓Currently using 1-2 concomitant marketed antiepileptic drugs (AEDs)
Key exclusion· 5
- ✕Known pseudoseizures within the past year
- ✕Progressive cerebral disease or progressively degenerative neurological disease
- ✕Cerebral tumors
- ✕Uncountable seizures (clusters) or history of convulsive status epilepticus within the last 5 years
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV, Open-label, Multi-center, Community-based Trial in Asia Studying the Safety and Efficacy of Keppra™ as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy.
In Brief
A Phase 4 clinical trial evaluating Levetiracetam for Epilepsy, Partial. Completed, enrolled 251 participants across 29 sites in 6 countries.
Detailed Summary
Community based study assessing safety and efficacy of levetiracetam in partial onset seizures. The optimal dose in daily clinical practice will be used.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy, Partial
CountriesHong Kong, Malaysia, Philippines, Singapore, Taiwan, Thailand
Collaborators--
Timeline
Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2003
First PostedSep 2005
Primary CompletionDec 2006
TodayJul 2026
First PostedSep 12, 2005
Enrollment StartNov 24, 2003
Primary CompletionDec 12, 2006
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 20.8 years ago
Interventions
Levetiracetamdrug
* Pharmaceutical form: oral tablets * Concentration: 500 mg * Route of administration: Oral use